Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

5.190 +0.140 (+2.77%)
Streaming Delayed Price Updated: 1:34 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
From Avacta Group PLC
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
PPHC Added to Russell 2000® and Russell 3000® Indexes
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
Public Policy Holding Company, Inc. Announces Full Year 2025 Financial Results
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
PPHC Announces Acquisition of WPI Strategy
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC Expands Strategic Advisory Platform with Appointment of TrailRunner Sports President
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC To Report Fourth Quarter and Full Year 2025 Financial Results on March 23, 2026
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Reports 2025 Full Year Results and Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
From Avacta Group PLC
Via GlobeNewswire
News headline image
Leishen Energy Holding Co., Ltd. Announced Fiscal Year 2025 Financial Results Highlighting Strong Operating Cash Flow and Low Financial Leverage
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
News headline image
Corero Network Security to Present at the AI & Technology Virtual Investor Conference February 19th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Avacta appoints Francis Wilson as Chief Scientific Officer
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2025 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
Cardiac dosing limit removed and path forward to dose selection identified 
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Interim Results for the six months ended 31 October 2025
From Scancell Holdings Plc
Via GlobeNewswire
News headline image
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
From Scancell Holdings Plc
Via GlobeNewswire
News headline image
Leishen Energy Holding Co., Ltd. Announces Receipt of Nasdaq Notice Regarding Annual Meeting Requirement
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
News headline image
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Avacta Announces Year-end Trading Update
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.